(Q39270840)

10 September 2017

title

KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines (English)

1 reference

10 September 2017

1 reference

1 reference

1 reference

4

0 references

author name string

Isabelle Messner

1

1 reference

10 September 2017

Giuseppe Cadeddu

2

1 reference

10 September 2017

Wolfgang Huckenbeck

3

1 reference

10 September 2017

Helmut E Gabbert

5

1 reference

10 September 2017

Stephan E Baldus

6

1 reference

10 September 2017

Karl-Ludwig Schaefer

7

1 reference

10 September 2017

publication date

27 September 2012

1 reference

Journal of Cancer Research and Clinical Oncology

10 September 2017

published in

1 reference

10 September 2017

volume

139

1 reference

10 September 2017

issue

2

1 reference

10 September 2017

page(s)

201-209

1 reference

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Recurrent KRAS codon 146 mutations in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Clinical relevance of KRAS in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1319-7

Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression

21 January 2018

1 reference

12 December 2020

Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis

1 reference

12 December 2020

Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases

1 reference

12 December 2020

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

12 December 2020

Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab

1 reference

12 December 2020

K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression.

1 reference

12 December 2020

Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab

1 reference

12 December 2020

Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors

1 reference

12 December 2020

10.1007/S00432-012-1319-7

Identifiers

DOI

1 reference

release_vjkmxwmiinb5ndxfxo6hoyjs5m

10 September 2017

Fatcat ID

0 references

1 reference